+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global BRAF Kinase Inhibitors Market 2019-2023 - Product Image

Global BRAF Kinase Inhibitors Market 2019-2023

  • ID: 4774814
  • Report
  • Region: Global
  • 125 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Array BioPharma Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • MORE
Prominent drugs based on BRAF kinase inhibitors, such as dabrafenib and sorafenib, are revolutionizing the therapeutic strategies of HCC, RCC, NSCLC, and melanomas. However, the high costs of these drugs remain a challenge to patients as well as the healthcare system. To overcome this challenge, many government and non-government organizations, including pharmaceutical companies, are focusing on providing financial assistance and clinical assistance for the treatment of various cancer indications. Effective patient assistance programs and reimbursement programs are expected to help with the high-cost regimen of BRAF kinase inhibitors to a large extent, which would encourage more patients to avail the treatment, thereby driving the market growth. Analysts have predicted that the BRAF kinase inhibitors market will register a CAGR of over 8% by 2023.

Market Overview

Increasing prevalence of cancer

The prevalence of cancer has seen a significant rise in recent years globally, and the global pharmaceuticals market has witnessed the approval of various novel therapies, especially in the field of oncology. Hence, various companies are conducting heavy research on developing novel therapeutics, such as BRAF kinase inhibitors, to capture the huge unmet need, and the market has witnessed the approval of these drugs in the last two decades. Currently, BRAF kinase inhibitors are approved for some of the major cancers such as NSCLC, metastatic melanomas, and RCC. Therefore, the strong prevalence of various cancer indications is driving the growth of the global BRAF kinase inhibitors market.

Adverse effects of available drugs

BRAF kinase inhibitor therapeutics demonstrate a range of adverse effects such as fatigue, muscle cramps, nausea, vomiting, and diarrhea. The combination of BRAF kinase inhibitors and radiation therapy often leads to cytotoxic effects and myelosuppression. Despite being highly efficacious, the BRAF kinase inhibitors used for treating some of the oncology indications are associated with a spectrum of side effects. These side effects limit patient adherence to treatments, which poses a challenge to the market.

Competitive Landscape

The market appears to be moderately concentrated. The presence of few companies, including Array BioPharma Inc. and Bayer AG makes the competitive environment quite intense. Factors such as the improvements in production technology of BRAF kinase inhibitors and the growing demand for renewable energy and sustainable products will provide significant growth opportunities to the BRAF kinase inhibitor drug manufacturers. F. Hoffmann-La Roche Ltd., and Novartis AG. are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Array BioPharma Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Dabrafenib - Market size and forecast 2018-2023
  • Sorafenib - Market size and forecast 2018-2023
  • Vemurafenib - Market size and forecast 2018-2023
  • Encorafenib - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 12: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Array BioPharma Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
PART 13: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits:
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Dabrafenib - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Dabrafenib - Year-over-year growth 2019-2023 (%)
Exhibit 21: Sorafenib - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Sales data of sorafenib
Exhibit 23: Sorafenib - Year-over-year growth 2019-2023 (%)
Exhibit 24: Vemurafenib - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Vemurafenib - Year-over-year growth 2019-2023 (%)
Exhibit 26: Encorafenib - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Encorafenib - Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in North America
Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Europe
Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in Asia
Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in ROW
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Patient assistance programs
Exhibit 47: New cases of cancer in the US 2015
Exhibit 48: Alternative therapies based on BRAF kinase inhibitors for various oncology indications
Exhibit 49: Side effects of BRAF kinase inhibitors
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Approved drugs with respect to their cancer indications
Exhibit 52: Expansion of research areas of BRAF kinase inhibitors
Exhibit 53: Strategic alliances in global BRAF kinase inhibitors market
Exhibit 54: Vendor landscape
Exhibit 55: Landscape disruption
Exhibit 56: Vendors covered
Exhibit 57: Vendor classification
Exhibit 58: Market positioning of vendors
Exhibit 59: Array BioPharma Inc. - Vendor overview
Exhibit 60: Array BioPharma Inc. - Business segments
Exhibit 61: Array BioPharma Inc. - Organizational developments
Exhibit 62: Array BioPharma Inc. - Geographic focus
Exhibit 63: Array BioPharma Inc. - Key offerings
Exhibit 64: Array BioPharma Inc. - Key customers
Exhibit 65: Bayer AG - Vendor overview
Exhibit 66: Bayer AG - Business segments
Exhibit 67: Bayer AG - Organizational developments
Exhibit 68: Bayer AG - Geographic focus
Exhibit 69: Bayer AG - Segment focus
Exhibit 70: Bayer AG - Key offerings
Exhibit 71: Bayer AG - Key customers
Exhibit 72: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 73: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 74: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 75: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 76: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 77: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 78: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 79: Novartis AG - Vendor overview
Exhibit 80: Novartis AG - Business segments
Exhibit 81: Novartis AG - Organizational developments
Exhibit 82: Novartis AG - Geographic focus
Exhibit 83: Novartis AG - Segment focus
Exhibit 84: Novartis AG - Key offerings
Exhibit 85: Novartis AG - Key customers
Exhibit 86: Validation techniques employed for market sizing
Exhibit 87: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Array BioPharma Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • MORE
The following companies are recognised as the key players in the global BRAF kinase inhibitors market: Array BioPharma Inc., Bayer AG, F. Hoffmann-La Roche Ltd., and Novartis AG.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the growing awareness of cancer.”

According to the report, one of the major drivers in this market is the high target affinity and specificity of BRAF kinase inhibitors.

Further, the report states that one of the major factors hindering the growth of this market is the adverse effects of available drugs.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Array BioPharma Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
Note: Product cover images may vary from those shown
Adroll
adroll